- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02987400
Combination of Obinutuzumab and Venetoclax in Relapsed or Refractory DLBCL
Phase II Single-arm "Window-of-opportunity" Study of a Combination of Obinutuzumab (GA-101) and Venetoclax (ABT-199) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study will have a 6 patient run-in phase to determine safety and to adjust treatment. Once the sixth patient has completed 21 days of treatment, withdrawn due to toxicity, or died, a formal review will be undertaken by the sponsor (AGMT). Enrolment will be halted until review is completed. If one (1) treatment related death is reported or three (3) or more patients experience CTC grade 4 events other than neutropenia, anemia, or thrombocytopenia, the study will be stopped for further recruitment. If the stopping criteria are not met, enrollment will be continued. A futility analysis will be conducted when the first 10 patients have been evaluated for response: If at least 2 patients had an objective response (CR or PR), the study will be continued.
The combination treatment will be repeated for up to 3 cycles. The first response assessment (including PET-CT) will be performed after the first cycle of obinutuzumab-venetoclax and patients with at least stable disease (SD) or better will be given another 2 cycles of therapy and then have assessment after a total of 3 cycles. Patients with complete or partial remission (CR, PR) after 3 cycles of therapy will either go on to transplant or receive 9 further cycles of the combination therapy (if transplant ineligible). Patients with progressive disease at any time-point or stable disease after 3 cycles will be taken off study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Graz, Austria, 8036
- UK Graz: Universitätsklinik für Innere Medizin; Klinische Abteilung für Hämatologie
-
Innsbruck, Austria, 6020
- Medizinische Universität Innsbruck Univ.-Klinik für Innere Medizin V Hämatologie und Onkologie
-
Linz, Austria, 4021
- Kepler Universitätsklinikum Linz, Med Campus III.,Univ.-Klinik für Hämatologie und Internistische Onkologie
-
Salzburg, Austria, 5020
- Universitätsklinik für Innere Med. III, PMU Salzburg
-
Vienna, Austria, 1090
- AKH Meduni Wien Universitätsklinik für Innere Medizin I Klinische Abteilung für Hämatologie und Hämostaseologie
-
Wels, Austria, 4600
- Klinikum Wels-Grieskirchen, Abteilung für Innere Medizin IV
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Diffuse large B-cell lymphoma (DLBCL)
- with histologically confirmed relapse within 12 months after having achieved a PR or CR with initial R-anthracycline containing therapy, or
- with refractoriness to initial R-anthracycline containing therapy (not achieving at least a partial response)
- Bcl-2 protein expression detected by immunohistochemistry.
- Adequate organ function,
- At least one bi-dimensionally measurable lesion on CT scan defined as > 1.5 cm in its longest dimension.
- Confirmed availability of archival or freshly biopsied tumor tissue meeting protocol-defined-specifications prior to study enrolment.
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2.
- Adequate hematologic function (unless caused by underlying disease, as established by extensive bone marrow involvement or as a result of hypersplenism secondary to the involvement of the spleen by lymphoma per the investigator)
Exclusion Criteria:
- Patient has received any other investigational treatment within 28 days before study entry.
- Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of obinutuzumab or venetoclax.
- DLBCL transformed from other malignancies or CD20 negative DLBCL.
- Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 4 weeks prior to Cycle 1 Day 1.
- Ongoing corticosteroid use > 30 mg/day of prednisone or equivalent. Patients who received corticosteroid treatment with ≤ 30 mg/day of prednisone or equivalent must be documented to be on a stable dose of at least 4 weeks duration prior to randomization (Cycle 1 Day 1). Patients may have received a brief (< 7 days) course of systemic steroids (≤ 100 mg prednisone equivalent) prior to initiation of study therapy for control of lymphoma-related symptoms.
- ECOG performance status ≥ 3.
- Female patients who are pregnant or breast-feeding.
- Acute or uncontrolled chronic infections.
- Known diagnosis of HIV
- Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of PML.
- Symptomatic neurologic disease compromising normal activities of daily living or requiring medications.
- Any sensory or motor peripheral neuropathy greater than or equal to Grade 2.
Known history of any of the following cardiovascular conditions:
- myocardial infarction within 2 years of study entry,
- New York Heart Association (NYHA) Class III or IV heart failure,
- evidence of current uncontrolled cardiovascular conditions, including cardiac arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities,
- recent evidence (within 6 months before first dose of study drug) of a left-ventricular ejection fraction <50% .
- Diagnosed or treated for another malignancy within 3 years before the first dose or previously diagnosed with another malignancy and have evidence of residual disease.
- Patients with transformed lymphoma.
- Primary CNS lymphoma.
- Vaccination with live vaccines within 28 days prior to treatment.
- History of other malignancy that could affect compliance with the protocol or interpretation of results (Patients with a history of curatively treated basal or squamous cell carcinoma or Stage 1 melanoma of the skin or in situ carcinoma of the cervix are eligible).
- Patients with a malignancy that has been treated with surgery alone with curative intent will also be excluded, unless the malignancy has been in documented remission without treatment for ≥ 3 years prior to enrollment.
- Evidence of significant, uncontrolled concomitant diseases that could affect compliance with the protocol or interpretation of results or that could increase risk to the patient.
- Significant pulmonary disease (including obstructive pulmonary disease and history of bronchospasm).
- Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major episode of infection requiring treatment with IV antibiotics or hospitalization (relating to the completion of the course of antibiotics) within 4 weeks prior to Cycle 1 Day 1.
- Requires the use of warfarin (because of potential drug-drug interactions that may potentially increase the exposure of warfarin).
Received the following agents within 7 days prior to the first dose of venetoclax:
- CYP3A inhibitors such as fluconazole, ketoconazole, and clarithromycin
- Strong CYP3A inducers such as rifampin, carbamazepine
- Consumed grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or star fruit within 3 days prior to the first dose of venetoclax.
- Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis.
- Presence of positive test results for Hepatitis B, Hepatitis C and CMV.
- Recent major surgery (within 6 weeks prior to the start of Cycle 1 Day 1), other than for diagnosis.
Any of the following abnormal laboratory values:
- Calculated creatinine clearance < 50 mL/min with the use of the 24-hour creatinine clearance or modified Cockcroft-Gault equation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment
Obinutuzumab is given in a 21 day cycle intravenously starting at 1000 mg on day 1, 8 and 15 in cycle 1 and on day 1 of each following cycle Venetoclax is given orally at a dose of 800mg daily from day 1 of the first cycle.
|
3 cycles followed by 9 cycles consolidation if not transplant eligible
Other Names:
3 cycles followed by 9 cycles consolidation if not transplant eligible
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical activity and tolerability
Time Frame: After 3 cycles of treatment (9 weeks)
|
Objective response rate (complete or partial responses; best response) defined by PET/CT scan and bone marrow examination examination after 3 cycles.
|
After 3 cycles of treatment (9 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Incidence of dose-limiting toxicities
Time Frame: 9 weeks induction plus maximum of 27 weeks consolidation
|
Incidence of dose-limiting toxicities of the combination treatment.
|
9 weeks induction plus maximum of 27 weeks consolidation
|
Response duration
Time Frame: From first documented response until end of follow up (max 108 weeks)
|
From first documented response until end of follow up (max 108 weeks)
|
|
Progression-free survival
Time Frame: 72 weeks after last patient last visit
|
72 weeks after last patient last visit
|
|
Overall survival
Time Frame: 72 weeks after last patient last visit
|
72 weeks after last patient last visit
|
|
Ability to proceed to further stem cell transplantation
Time Frame: After 3 cycles of treatment (9 weeks)
|
Assessed by number of eligible patients reaching transplant
|
After 3 cycles of treatment (9 weeks)
|
Genetically/biomarker defined subgroups
Time Frame: 72 weeks after last patient last visit
|
Identification of genetically/biomarker defined subgroups regarding response and survival
|
72 weeks after last patient last visit
|
Collaborators and Investigators
Collaborators
Investigators
- Study Director: Ulrich Jäger, MD, Medical University of Vienna
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Venetoclax
- Obinutuzumab
Other Study ID Numbers
- AGMT_NHL-15B
- 2016-001760-10 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma, Large B-Cell, Diffuse
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Lymphoma, B-Cell | DLBCL - Diffuse Large B Cell Lymphoma | Large B-cell Lymphoma | Large-cell Lymphoma | Mediastinal B-Cell Diffuse Large Cell LymphomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); AmgenActive, not recruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | CD20 Positive | Stage I Diffuse Large B-Cell Lymphoma | Stage II Diffuse Large B-Cell Lymphoma | Stage III Diffuse Large B-Cell Lymphoma | Stage IV Diffuse Large B-Cell LymphomaUnited States
-
Qian WenbinNot yet recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaChina
-
University Hospital Southampton NHS Foundation...Hoffmann-La RocheTerminatedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited Kingdom
-
National Cancer Institute (NCI)WithdrawnDiffuse, Large B-cell Lymphoma | Lymphoma, Diffuse Large-Cell | Lymphoma, Diffuse Large-Cell B-cell | Large-Cell Lymphoma, Diffuse
-
Dana-Farber Cancer InstituteBayer; AbbVieActive, not recruitingDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterSanofi; Columbia University; Medical College of Wisconsin; University of Rochester and other collaboratorsActive, not recruitingDiffuse Large B-cell Lymphoma (DLBCL) | Relapsed Diffuse Large B-cell Lymphoma (DLBCL) | Refractory Diffuse Large B-cell Lymphoma (DLBCL)United States
-
Autolus LimitedCompletedDiffuse Large B Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | DLBCL | Relapsed Diffuse Large B-Cell LymphomaUnited States, United Kingdom
-
Herlev HospitalOdense University Hospital; Zealand University Hospital; Aarhus University Hospital and other collaboratorsCompletedDiffuse Large B-cell Lymphoma Recurrent | Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Cell of Origin
-
UNC Lineberger Comprehensive Cancer CenterCephalonCompletedLymphoma | Diffuse Large B-Cell Lymphoma | Lymphoma, Diffuse Large-Cell | Diffuse Large-Cell LymphomaUnited States
Clinical Trials on Venetoclax
-
Virginia Commonwealth UniversityAbbVieWithdrawnRelapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
-
PrECOG, LLC.Genentech, Inc.CompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High GradeUnited States
-
University of Maryland, BaltimoreActive, not recruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States
-
Yale UniversityCompleted
-
Gruppo Italiano Malattie EMatologiche dell'AdultoRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic Lymphoma GroupActive, not recruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNordic CLL Study GroupActive, not recruitingChronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in RemissionNetherlands, Belgium, Denmark, Finland, Norway, Sweden
-
BioSight Ltd.Recruiting
-
The Lymphoma Academic Research OrganisationInstitute of Cancer Research, United KingdomRecruitingMantle Cell LymphomaFrance, United Kingdom, Belgium
-
Aptose Biosciences Inc.RecruitingRelapsed or Refractory Acute Myeloid LeukemiaUnited States, Germany, Spain, Korea, Republic of, Australia, New Zealand